[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515947":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":55,"centralContacts":60,"locations":65,"responsibleParty":88,"collaborators":91,"id":95,"slug":54,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":54,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":54,"enrollmentInfo":103,"targetDuration":54,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":54,"overallStatus":67,"whyStopped":54,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Emory University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (atovaquone)","EXPERIMENTAL","Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study.",[13,14,15,16],"Drug: Atovaquone","Procedure: Biopsy","Procedure: Computed Tomography","Procedure: Paracentesis",[18,28,36,50],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Atovaquone","Given PO",[9],[24,25,26,27],"566C80","BW-566C","BW-A566C","Mepron",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"PROCEDURE","Biopsy","Undergo biopsy",[9],[34,35],"BIOPSY_TYPE","Bx",{"type":29,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Computed Tomography","Undergo CT",[9],[41,42,43,44,45,46,47,48,49],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","CT","CT Scan","tomography",{"type":29,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"Paracentesis","Undergo paracentesis",[9],null,[56],{"name":57,"affiliation":58,"role":59},"Namita Khanna, MD, MSPH","Emory University Hospital\u002FWinship Cancer Institute","PRINCIPAL_INVESTIGATOR",[61],{"name":57,"role":62,"phone":63,"phoneExt":54,"email":64},"CONTACT","404-778-3401","namita.khanna@emory.edu",[66],{"facility":58,"status":67,"city":68,"state":69,"zip":70,"country":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"RECRUITING","Atlanta","Georgia","30322","United States",{"type":73,"coordinates":74},"Point",[75,76],-84.38798,33.749,{"lat":76,"lon":75},[79,83,87],{"name":80,"role":62,"phone":81,"phoneExt":54,"email":82},"Nina Kimball","404-778-8145","nina.cathleen.dobbs.kimball@emory.edu",{"name":84,"role":62,"phone":85,"phoneExt":54,"email":86},"Maisey S Ratcliffe","404-778-3449","maisey.shannon.ratcliffe@emory.edu",{"name":57,"role":59,"phone":54,"phoneExt":54,"email":54},{"type":59,"investigatorFullName":89,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":54,"oldOrganization":54},"Namita Khanna","Principal Investigator",[92],{"name":93,"class":94},"National Cancer Institute (NCI)","NIH","100515947",false,"NCT05998135","Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer","Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer","Inclusion Criteria:\n\n* Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy\n* Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* There will be no limitations on number of prior lines of therapy\n* Trial is open to non-English speaking patients\n* Trial is open to patients referred from community practice\n\nExclusion Criteria:\n\n* Patients who are \\\u003C 18 years old\n* Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)\n* Patients who are incarcerated\n* Patients who are unable to provide consent \u002F lack decision-making capacity","FEMALE","18 Years",{"count":104,"type":105},28,"ESTIMATED","INTERVENTIONAL",[108],"PHASE2","This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.",[111,112],"Ovarian High Grade Serous Adenocarcinoma","Platinum-Resistant Ovarian Carcinoma","2025-09-05",{"date":115,"type":116},"2025-09-11","ACTUAL",{"date":118,"type":116},"2023-11-09",{"date":120,"type":105},"2027-06-30",{"name":5,"class":6},1]